Scilex Unwinds Vivasor Stake in $12M Related-Party Sale
SCLX has more than doubled off its 52-week low of $2.615.
Summary
Scilex Holding Co. agreed to sell its Vivasor preferred shares back to Vivasor for $12 million in a related-party deal, providing cash but raising governance concerns.
Key Events · M&A and Partnerships · SCLX
-
Vivasor Stake Sold Back
Scilex sold 6,101,468 Series A-1 and 355,919 Series A-2 preferred shares of Vivasor back to Vivasor for $11,999,762.28, unwinding an investment made in January 2026.
-
Related-Party Transaction
Because Scilex CEO Henry Ji is also CEO of Vivasor, this qualifies as a related-party deal. The agreement includes broad releases of claims by Scilex against Vivasor.
-
Payment Structure
Vivasor pays in five tranches: $1M at signing, $5M by Sept 30, 2026, and three $2M payments through June 30, 2027. Vivasor can pay in cash or Datavault AI stock.
-
Liquidity Impact
The $12M provides cash to Scilex, which has a going-concern warning and negative operating cash flow, but the deferred payments mean only $1M is received upfront.
Analysis · SCLX · Life Sciences
Scilex is selling its entire stake in Vivasor Holding Company—6.1 million Series A-1 and 355,919 Series A-2 preferred shares—back to Vivasor for $12 million. The deal unwinds an investment made just six months ago and carries a related-party tag because Scilex CEO Henry Ji also leads Vivasor. Payment is spread over five tranches through mid-2027, and Vivasor can settle in cash or by handing over Datavault AI stock. For a company with a going-concern warning and negative cash flow, the $12 million provides near-term liquidity, but the structure and related-party nature raise governance questions.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCLX was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.7M. The 52-week trading range was $2.62 to $21.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.